Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial (Q37022421)

17 August 2017

Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial (English)

1 reference

17 August 2017

0 references

1 reference

9

Werner Poewe

1 reference

17 August 2017

3

Paolo Barone

1 reference

17 August 2017

10

Olivier Rascol

1 reference

17 August 2017

1

Anthony H V Schapira

1 reference

17 August 2017

8

Yoshikuni Mizuno

1 reference

17 August 2017

5

Stefan Albrecht

1 reference

17 August 2017

4

Cynthia L Comella

1 reference

17 August 2017

11

Kenneth Marek

1 reference

17 August 2017

Michael P McDermott

2

1 reference

PMCID

3714436

17 August 2017

Helen H Hsu

series ordinal

6

1 reference

PMCID

3714436

17 August 2017

Daniel H Massey

series ordinal

7

1 reference

17 August 2017

31 May 2013

1 reference

17 August 2017

1 reference

17 August 2017

12

1 reference

17 August 2017

747-755

1 reference

17 August 2017

8

1 reference

Glucocerebrosidase in the pathogenesis and treatment of Parkinson disease

17 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3714436

The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3714436

A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3714436

Defining disease-modifying therapies for PD--a road map for moving forward

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3714436

A double-blind, delayed-start trial of rasagiline in Parkinson's disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3714436

Why have we failed to achieve neuroprotection in Parkinson's disease?

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3714436

Neuroprotection trials in Parkinson's disease: systematic review

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3714436

Targets for neuroprotection in Parkinson's disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3714436

Timing of treatment initiation in Parkinson's disease: a need for reappraisal?

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3714436

Levodopa and the progression of Parkinson's disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3714436

Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3714436

Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3714436

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3714436

Parkinsonism: onset, progression, and mortality

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3714436

Rationale for delayed-start study of pramipexole in Parkinson's disease: the PROUD study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3714436

Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3714436

A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3714436

Continuous subcutaneous infusion of pramipexole protects against lipopolysaccharide-induced dopaminergic cell death without affecting the inflammatory response.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3714436

Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3714436

Pramipexole protects against MPTP toxicity in non-human primates.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3714436

Impulse control disorders in adult psychiatric inpatients.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3714436

A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3714436

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3714436

[123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3714436

Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3714436

Pramipexole in patients with early Parkinson's disease

4 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970117-0

inferred from DOI database lookup

7 January 2021

based on heuristic

Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group

1 reference

Crossref

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970117-0

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S1474-4422(13)70117-0

1 reference

17 August 2017

1 reference

17 August 2017

1 reference

PMCID

3714436